测试版
试验雷达 AI
临床试验 NCT05023993 针对造血和淋巴细胞肿瘤,恶性实体肿瘤,糖尿病前期目前进行中但不再招募。请查看临床试验雷达卡片视图和 AI 发现工具了解所有详情,或在此提出任何问题。
一个试验符合筛选条件
卡片视图

The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer

进行中但不再招募
临床试验详情主要以英语提供。然而,试验雷达 AI可以提供帮助!只需点击“解释临床试验”即可查看和讨论您选择的语言的试验信息。
临床试验NCT05023993是一项针对造血和淋巴细胞肿瘤,恶性实体肿瘤,糖尿病前期干预性研究试验,目前试验状态为进行中但不再招募。试验始于2022年6月23日,计划招募20名患者。该研究由希望之城国家医学中心主导,预计于2026年9月21日完成。试验数据来源于ClinicalTrials.gov,最后更新时间为2025年11月7日
简要概括
This trial studies the effect of exercise and nicotinamide riboside on muscle health and insulin resistance in adult survivors of childhood cancer with prediabetes (elevated blood sugar level that is not high enough to be considered diabetes). Nicotinamide riboside is a dietary supplement which is similar to vitamin B3. Information collected in this study may help the future development of regimens to improve metabolic outcomes such as muscle health and insulin resistance (when the body is not normally responding to insulin) in childhood cancer survivors.
详细描述
PRIMARY OBJECTIVE:

I. Evaluate the feasibility of conducting a home exercise and nutrition intervention in childhood cancer survivors (CCS) with a history of prediabetes.

EXPLORATORY OBJECTIVES:

I. Describe the association between patient demographics and treatment exposures and subsequent hyperglycemia and skeletal muscle health in childhood cancer survivors.

II. Describe the effect of exercise with or without nicotinamide riboside (NR) on hyperglycemia and skeletal muscle health in CCS with a history of prediabetes.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for 6 weeks.

ARM II: Patients complete home exercise as in Arm I. Patients also receive nicotinamide riboside orally (PO) daily for 6 weeks.

官方标题

The Effect of Exercise and Nicotinamide Riboside on Muscle Health and Insulin Resistance in Adult Survivors of Childhood Cancer With Prediabetes: A Pilot Feasibility Study

疾病
造血和淋巴细胞肿瘤恶性实体肿瘤糖尿病前期
其他研究标识符
NCT编号
实际开始日期
2022-06-23
最近更新发布
2025-11-07
预计完成日期
2026-09-21
计划入组人数
20
研究类型
干预性研究
试验分期 (阶段)
不适用
试验状态
进行中但不再招募
主要目的
支持治疗
分配方式
随机
干预模型
平行
盲法
无(开放性试验)
试验组/干预措施
参与者组/试验组干预措施/治疗方法
阳性对照Arm I (home exercise)
Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for 6 weeks.
运动干预
Complete home exercise
实验性Arm II (home exercise, nicotinamide riboside)
Patients complete home exercise as in Arm I. Patients also receive nicotinamide riboside PO daily for 6 weeks.
运动干预
Complete home exercise
Nicotinamide Riboside
Given PO
主要终点
结果指标度量标准描述时间框架
Feasibility of a nutrition and exercise program in childhood cancer survivors (CCS)
The current protocol will be considered feasible if: 1. \>= 50% of eligible patients that are approached for participation enroll onto the study, 2. \>= 70% of enrolled participants successfully complete all study assessments (i.e. physical function tests, blood draw, imaging, and questionnaires at baseline and 6 weeks, and 3. Enrolled participants demonstrate \>= 70% compliance with prescribed exercise and nicotinamide riboside. Feasibility measures 2 and 3 will be assessed for the entire group of 20 subjects as a whole.
Up to 6 weeks
资格标准

适龄参与研究
成人, 老年人
最低年龄要求
18 Years
适龄性别
全部
  • History of childhood cancer
  • History of prediabetes (HbA1c 5.7-6.4%)
  • In remission at time of enrollment
  • Time between completion of cancer-directed therapy and study entry: >= 6 months
  • At least 18 years of age at time of enrollment
  • Able to access online exercise program at home
  • Ability to tolerate the prescribed resistance exercise program
  • English-speaking
  • Able to understand and sign the study specific informed consent form (ICF)

  • Taking a nicotinamide adenine dinucleotide (NAD)+ precursor in the two weeks prior to enrollment
  • Currently taking medication for hyperglycemia or diabetes
  • Females who are pregnant or planning to become pregnant
  • Currently recovering from an injury
  • Contraindication to magnetic resonance imaging (MRI)
  • Pacemaker
没有联系数据。
1 位于 1 个国家/地区的研究中心

California

City of Hope Medical Center, Duarte, California, 91010, United States